Does docetaxel-ST1481 sequence exert a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression?
Our results show that the Doc --> ST1481 sequence effectively reduces the cancer cell population and restores Doc activity in taxane-resistant HRPC, indicating its potential usefulness as first- or second-line treatment of hormone-refractory prostate cancer.
Thus, tongue and buccal cancers represent different biological subentities, and such differences should be considered in oral cancer management.